Abattis Bioceuticals Corp (CNSX:ATT) Director William Panenka sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of C$0.67, for a total transaction of C$16,750.00.

William Panenka also recently made the following trade(s):

  • On Friday, January 12th, William Panenka sold 90,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.53, for a total transaction of C$47,700.00.
  • On Tuesday, December 12th, William Panenka sold 100,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.48, for a total transaction of C$48,000.00.

Abattis Bioceuticals Corp (CNSX:ATT) opened at C$0.61 on Monday. Abattis Bioceuticals Corp has a 12-month low of C$0.05 and a 12-month high of C$0.74. The company has a market cap of $136.43 and a price-to-earnings ratio of -15.25.

COPYRIGHT VIOLATION NOTICE: “Abattis Bioceuticals Corp (ATT) Director Sells C$16,750.00 in Stock” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2018/01/22/abattis-bioceuticals-corp-att-director-sells-c16750-00-in-stock.html.

Abattis Bioceuticals Company Profile

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets.

Receive News & Ratings for Abattis Bioceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abattis Bioceuticals and related companies with MarketBeat.com's FREE daily email newsletter.